Proteolysis targeting chimeras (PROTACs) are small molecules capable of targeting disease-relevant proteins for degradation by the ubiquitin-proteasome pathway. The ability to target and destroy a specific protein-of-interest (POI) have made protein degrader molecules promising candidates for developing novel anticancer therapeutics. In this webinar brought to you by BPS Bioscience, Amar Natarajan and Guangrong Zheng will discuss the development and applications of PROTACs for cancer therapy.

Topics to be covered

• PROTACs targeting hepatocyte growth factor receptor mutants
• PROTACs to improve tissue selectivity
  • 1644951134-a2675978b85836c0
    Amar Natarajan, PhD
    Professor, Eppley Institute for Research in Cancer and Allied Diseases, Co-leader, Targets Modulators and Delivery Program (TMDP), Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center
    Amar Natarajan is the Ruth Branham Professor of Cancer Research at the University of Nebraska Medical Center (UNMC), Omaha. Natarajan earned a MS in chemistry from the Indian Institute of Technology, Madras, and a PhD in organic chemistry from the University of Vermont (UVM). Following postdoctoral training at Harvard Medical School, Natarajan started his independent career in the Chemical Biology Program at the University of Texas. He researches the discovery and development of target and mechanism-specific small molecule inhibitors/perturbants against disease relevant targets.
  • 1644951202-81382ecf43d20b1c
    Guangrong Zheng, PhD
    Associate Professor, Department of Medicinal Chemistry, College of Pharmacy, University of Florida
    Guangrong Zheng is an associate professor in the Department of Medicinal Chemistry at the University of Florida College of Pharmacy. His group focuses on the discovery and development of targeted protein degraders for cancer treatment. Zheng received his PhD in organic chemistry from Shanghai Institute of Materia Medica and his BS in medicinal chemistry from Fudan University in Shanghai, China.